Investment Thesis

Biogen Inc. (BIIB) is a BUY at current prices, trading at $187.57, driven by its strong position in the neurological and neurodegenerative disease markets. Despite short-term volatility and market skepticism regarding its Alzheimer’s portfolio, particularly Aduhelm, the company's robust pipeline and established therapies position it favorably for long-term growth. The market is underestimating Biogen's potential for revenue recovery and innovation in a sector that is poised for substantial expansion.

Competitive Moat

is anchored in its intangible assets, notably its intellectual property and regulatory approvals for critical therapies such as TECFIDERA and SPINRAZA. The company's established brand reputation in neurology creates substantial switching costs for healthcare providers and patients, reinforcing customer loyalty. Over the next 5-10 years, this advantage appears durable, although competition from emerging biosimilars and new entrants in the Alzheimer’s treatment space poses a significant threat, particularly from companies like Eli Lilly and Roche.

Growth Engine

Future revenue growth for Biogen is anticipated to stem from both its existing therapies and a promising pipeline targeting neurological disorders. The total addressable market (TAM) for Alzheimer’s treatments alone is projected to reach over $30 billion by 2027, as the global prevalence of dementia continues to rise. Additionally, Biogen's ongoing efforts in geographic expansion and product line diversification, particularly in underpenetrated markets, are expected to bolster organic growth. The company is regaining market share in multiple sclerosis treatments, further enhancing its revenue prospects.